GlassScriptPhysician profile
Kiran Mahmood
NPI 1376982520
$28,476.89
in general payments reported to CMS, 2019-2025
32 companies · $5,116 in 2025
The $5,116 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,210 · 2020: $1,293 · 2021: $2,412 · 2022: $5,124 · 2023: $6,225 · 2024: $5,097 · 2025: $5,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $4,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,023.54 |
| Travel and Lodging | $4,414.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,664.84 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $8,260.54 | 2022-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $1,979.78 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Novo Nordisk INC | $1,297.48 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $1,259.81 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $519.14 | 2019-2022 | |
| Aop Health US, LLC | $515.87 | 2025 | Rapiblyk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.56 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $489.74 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $462.56 | 2022-2025 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $459.64 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $368.68 | 2019-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $318.06 | 2022-2023 | Optimizer |
| Merck Sharp & Dohme LLC | $307.02 | 2022-2025 | Verquvo |
| Bardy Diagnostics, INC. | $280.36 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $234.89 | 2021-2025 | Nexletol |
| Ancora Heart, INC. | $224.28 | 2023 | Accucinch |
| Heartflow, INC. | $221.12 | 2025 | |
| Scpharmaceuticals INC. | $205.16 | 2023-2025 | |
| Biotronik INC. | $176.23 | 2021 | |
| Irhythm Technologies, INC. | $174.94 | 2019 | |
| Abiomed | $112.14 | 2025 | |
| Lilly USA, LLC | $64.32 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $62.40 | 2022-2025 | |
| Akcea Therapeutics, INC. | $55.42 | 2020-2021 | |
| Pfizer INC. | $47.23 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.06 | 2019-2020 | |
| Daiichi Sankyo INC. | $44.97 | 2022-2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $41.36 | 2023 | Inpefa |
| Shockwave Medical, INC | $35.21 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $29.75 | 2024 | (Br3) Coronary Other |
| Cmp Pharma, INC. | $24.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.